Novavax Inc (NVAX) — closed signal from May 6, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 4, 2026.
Predicted vs. what happened
NVAX price · publication thesis → realized outcomesplit-adjusted
$7.90 – $8.70Entry zone — fair-value band
$8.53Published — price the day we called it
$10.57Target — the price the thesis aimed for
$11.61Peak — highest point inside the window, not a realized return
$7.66Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 2 days.
Peak price
$11.61
peak on May 27, 2026 — not a realized returnPeak gain
+36.1%
peak, from the publication priceWindow close
$7.66
end-of-window price, context onlyDays to target
2
Window
May 6, 2026 – August 4, 2026
The thesis — published May 6, 2026
Predicted growth
+24%
over the measurement windowTarget price
$10.57
the price the thesis aimed forEntry zone
$7.90 – $8.70
the fair-value band we waited forPrice at publication
$8.53
published May 6, 2026Confidence
68%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novavax is a risky but potentially high-reward biotech story. A shift toward licensing and upcoming vaccine results could quickly improve the outlook, and the stock looks cheap enough to attract interest. However, drug-development swings, many traders betting against the stock, and uneven earnings make this a short-term speculation best treated cautiously.
Primary drivers
- Licensing shift can cut the company's cash needs and financial risk
- Positive vaccine results can change how investors value the company
- A stronger balance sheet helps fund development through trials
- High short interest can make positive news produce large price moves
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.